Systemic barriers block access to HIV prevention breakthrough Lenacapavir despite its potential to end epidemics
Original framing: “Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs” — STAT News
The original framing omits the role of patent monopolies enforced by WTO rules, the historical underfunding of public health systems in Africa and Asia due to structural adjustment policies, and the exclusion of indigenous and traditional healers who have long managed HIV-related care. It also ignores the disproportionate impact on marginalized groups like sex workers, LGBTQ+ communities, and people in conflict zones, as well as the potential of community-led distribution models tested in places like Kenya and Brazil.
Medium structural omission detected in mainstream coverage.
The narrative is produced by STAT News, a platform catering to biomedical elites and policymakers, with framing that aligns with pharmaceutical industry interests. It serves corporate actors by framing pricing as a market-based solution while obscuring the role of patent regimes, lobbying, and historical exploitation in shaping access. The framing also privileges Western biomedical expertise over grassroots health workers and affected communities.
The HIV epidemic is deeply tied to colonial legacies, including the extraction of resources and the disruption of local health systems in Africa and Asia. Structural adjustment policies in the 1980s-90s forced cuts to public health budgets, exacerbating vulnerability to HIV. The current patent regime, enshrined in TRIPS, mirrors colonial-era resource extraction by prioritizing corporate profits over global health. Historical parallels include the 19th-century cholera epidemics, where colonial powers blamed local practices rather than systemic water infrastructure failures.
The Lenacapavir pricing debate exemplifies how biomedical breakthroughs are trapped in a colonial-capitalist framework that prioritizes profit over people.